First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer : LIGHT-NING study
© The Author(s) 2024. Published by Oxford University Press..
OBJECTIVE: As first-line treatment for stage IV or recurrent non-small cell lung cancer, combination immunotherapy with nivolumab and ipilimumab, with or without chemotherapy, had demonstrated survival benefits over chemotherapy; however, data on Japanese patients are limited.
METHODS: LIGHT-NING was a multicenter, observational study and retrospectively collected data. In this interim analysis, we analyzed patients who received combination immunotherapy between 27 November 2020 and 31 August 2021 for the treatment status, safety objectives (treatment-related adverse events and immune-related adverse events incidences), and effectiveness objectives (objective response rate and progression-free survival) to determine the characteristics and early safety information.
RESULTS: We analyzed 353 patients, with a median follow-up of 7.1 (interquartile range, 5.0-9.7) months. Overall, 60.1 and 39.9% received nivolumab plus ipilimumab with and without chemotherapy, respectively. In these cohorts, the median age was 67 and 72 years; 10.8 and 35.5% were aged ≥75 years; 80.2 and 79.4% were male; 5.2 and 13.5% had a performance score ≥ 2; 32.1 and 27.0% developed grade 3-4 immune-related adverse events; treatment-related deaths were observed in 6 (2.8%) and 5 (3.5%) patients, respectively. Grade 3-4 immune-related adverse event incidence was the highest within the first month of treatment in both cohorts, although the immune-related adverse event risk persisted throughout. No new safety signals were observed at this interim analysis. The median progression-free survival was 6.0 (95% confidence interval, 5.2-7.6) and 5.8 (4.3-7.0) months in nivolumab plus ipilimumab with and without chemotherapy cohorts, respectively.
CONCLUSIONS: LIGHT-NING offers valuable insights into combination immunotherapy for untreated patients with stage IV or recurrent non-small cell lung cancer in Japanese real-world settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Japanese journal of clinical oncology - 54(2024), 4 vom: 06. Apr., Seite 452-462 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Imai, Hisao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
31YO63LBSN |
|---|
| Anmerkungen: |
Date Completed 09.04.2024 Date Revised 10.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jjco/hyad195 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367615800 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367615800 | ||
| 003 | DE-627 | ||
| 005 | 20240410232433.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240126s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jjco/hyad195 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM367615800 | ||
| 035 | |a (NLM)38271158 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Imai, Hisao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer |b LIGHT-NING study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2024 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press. | ||
| 520 | |a OBJECTIVE: As first-line treatment for stage IV or recurrent non-small cell lung cancer, combination immunotherapy with nivolumab and ipilimumab, with or without chemotherapy, had demonstrated survival benefits over chemotherapy; however, data on Japanese patients are limited | ||
| 520 | |a METHODS: LIGHT-NING was a multicenter, observational study and retrospectively collected data. In this interim analysis, we analyzed patients who received combination immunotherapy between 27 November 2020 and 31 August 2021 for the treatment status, safety objectives (treatment-related adverse events and immune-related adverse events incidences), and effectiveness objectives (objective response rate and progression-free survival) to determine the characteristics and early safety information | ||
| 520 | |a RESULTS: We analyzed 353 patients, with a median follow-up of 7.1 (interquartile range, 5.0-9.7) months. Overall, 60.1 and 39.9% received nivolumab plus ipilimumab with and without chemotherapy, respectively. In these cohorts, the median age was 67 and 72 years; 10.8 and 35.5% were aged ≥75 years; 80.2 and 79.4% were male; 5.2 and 13.5% had a performance score ≥ 2; 32.1 and 27.0% developed grade 3-4 immune-related adverse events; treatment-related deaths were observed in 6 (2.8%) and 5 (3.5%) patients, respectively. Grade 3-4 immune-related adverse event incidence was the highest within the first month of treatment in both cohorts, although the immune-related adverse event risk persisted throughout. No new safety signals were observed at this interim analysis. The median progression-free survival was 6.0 (95% confidence interval, 5.2-7.6) and 5.8 (4.3-7.0) months in nivolumab plus ipilimumab with and without chemotherapy cohorts, respectively | ||
| 520 | |a CONCLUSIONS: LIGHT-NING offers valuable insights into combination immunotherapy for untreated patients with stage IV or recurrent non-small cell lung cancer in Japanese real-world settings | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Japan | |
| 650 | 4 | |a ipilimumab | |
| 650 | 4 | |a nivolumab | |
| 650 | 4 | |a non-small-cell lung carcinoma | |
| 650 | 4 | |a observational study | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 650 | 7 | |a Ipilimumab |2 NLM | |
| 700 | 1 | |a Kijima, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Azuma, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Kishi, Kazuma |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Haruhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yamaguchi, Teppei |e verfasserin |4 aut | |
| 700 | 1 | |a Tanizaki, Junko |e verfasserin |4 aut | |
| 700 | 1 | |a Yoneshima, Yasuto |e verfasserin |4 aut | |
| 700 | 1 | |a Fujita, Kohei |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kitazono, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Fukuhara, Tatsuro |e verfasserin |4 aut | |
| 700 | 1 | |a Hataji, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Toi, Yukihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Mizutani, Hideaki |e verfasserin |4 aut | |
| 700 | 1 | |a Hamakawa, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Maemondo, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Ohsugi, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Horinouchi, Hidehito |e verfasserin |4 aut | |
| 700 | 1 | |a Ohe, Yuichiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Japanese journal of clinical oncology |d 1983 |g 54(2024), 4 vom: 06. Apr., Seite 452-462 |w (DE-627)NLM012592978 |x 1465-3621 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2024 |g number:4 |g day:06 |g month:04 |g pages:452-462 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jjco/hyad195 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2024 |e 4 |b 06 |c 04 |h 452-462 | ||